UNSPSC 51172320: Deferasirox

This classification denotes a metal chelator with the molecular formula C21H15N3O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier V8G4MOF2V9, chemically known as 4-(3,5-bis-(hydroxy-phenyl)-1,2,4)triazol-1-yl)-benzoic acid but generally known as deferasirox, which bears US NIH Compound Identifier 5493381. European Medicines Agency schedules Deferasirox in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB21981.

UNSPSC 51172320 Deferasirox (Commodity) shows minimal alignment with recent state and local procurement activity. The code nominally describes deferasirox, an oral iron-chelation pharmaceutical used to treat chronic iron overload in patients with transfusion-dependent anemia and other iron-storage disorders. State and local governments do procure pharmaceuticals through health departments, Medicaid agencies, and institutional healthcare systems, but the single recent opportunity tagged to this code—Collin County Community Supervision and Corrections Department's RFP 2026-327 for offender specimen collection and drug testing services—involves laboratory testing infrastructure, staffing, and immunoassay/confirmatory screening (LC/MS/MS, GC/MS, oral fluid, hair analysis), not pharmaceutical procurement. The mismatch suggests a coding error in the source rather than genuine market activity for deferasirox at the state or local level.

No recent state and local opportunities directly soliciting deferasirox or comparable iron-chelation pharmaceuticals appear in the available records. Procurement activity under this Commodity code, if present, would typically originate from state Medicaid programs, health departments, or institutional healthcare providers (county hospitals, correctional-health clinics), but no such solicitations are documented here. Business development professionals evaluating this code should verify whether deferasirox demand exists through direct outreach to state pharmacy benefit managers, Medicaid managed care organizations, and institutional health systems rather than relying on posted procurement notices.